Benzinga - by Lisa Levin, Benzinga Editor.
The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Omeros
- The Trade: Omeros Corporation (NASDAQ: OMER) Director MD Peter Demopulos acquired a total of 10,000 shares an average price of $1.53. To acquire these shares, it cost around $15,300.
- What’s Happening: Omeros posted a wider loss for the third quarter.
- What Omeros Does: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders.
- The Trade: Taysha Gene Therapies, Inc. (NASDAQ: TSHA) 10% owner Paul Manning acquired a total of 100,000 shares at an average price of $1.63. To acquire these shares, it cost around $163,000.
- What’s Happening: Taysha Gene Therapies posted a wider third-quarter loss.
- What Taysha Gene Therapies Does: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease.
Gannett
- The Trade: Gannett Co., Inc. (NYSE: GCI) Director Laurence Tarica acquired a total of 200,000 shares at an average price of $1.85. The insider spent around $370,000 to buy those shares.
- What’s Happening: Gannett and USA TODAY disclosed a multi-year strategic partnership with Home Solutions.
- What Gannett Does: Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Atai Life Sciences - The Trade: Atai Life Sciences N.V. (NASDAQ: ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares.
- What’s Happening: The company said net income attributable to shareholders for the three months ended Sept. 30, 2023 was $44.2 million.
- What Atai Life Sciences Does: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.